Actively Recruiting
Safety and Effects of Multiple Oral Doses of Inno8 in Males With Haemophilia A
Led by Novo Nordisk A/S · Updated on 2026-09-18
30
Participants Needed
33
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how different doses of a study medicine called Inno8 work in the bodies of people with haemophilia A. The purpose is to see if Inno8 is safe for use in this condition. This is a phase 1 treatment study sponsored by Novo Nordisk AS, lasting about 11 weeks, involving adult males with haemophilia A. Participants will receive oral doses of the study drug NNC0442-0344 A across three experimental cohorts. The dosing will be monitored closely throughout the study period. The study is designed as a single-group, non-randomized trial without blinding. During the study, participants will be evaluated for side effects and blood markers related to coagulation, such as D-dimer, prothrombin fragments, fibrinogen, and platelets. Researchers will also measure drug concentration levels and immune response indicators from the first dose through to the end of follow-up at Day 46. Safety assessments will be ongoing to monitor adverse events during the treatment and follow-up period.
CONDITIONS
Brief Title
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Research Team
N
Novo Nordisk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here